S
LGND icon

SignatureFD’s Ligand Pharmaceuticals LGND Stock Holding History

SignatureFD’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.5K Buy
283
+1
+0.4% +$236 ﹤0.01% 1510
2026
Q1 		$56.3K Buy
282
+3
+1% +$594 ﹤0.01% 1660
2025
Q4 		$52.8K Sell
279
-4
-1% -$769 ﹤0.01% 1617
2025
Q3 		$50.1K Sell
283
-18
-6% -$2.68K ﹤0.01% 1638
2025
Q2 		$34.2K Hold
301
– – ﹤0.01% 1789
2025
Q1 		$31.6K Hold
301
– – ﹤0.01% 1824
2024
Q4 		$32.3K Hold
301
– – ﹤0.01% 1809
2024
Q3 		$30.1K Hold
301
– – ﹤0.01% 1845
2024
Q2 		$25.4K Sell
301
-12
-4% -$955 ﹤0.01% 1843
2024
Q1 		$22.9K Hold
313
– – ﹤0.01% 1936
2023
Q4 		$22.4K Buy
313
+208
+198% +$12.3K ﹤0.01% 1874
2023
Q3 		$6.29K Hold
105
– – ﹤0.01% 2409
2023
Q2 		$7.57K Sell
105
-37
-26% -$2.78K ﹤0.01% 2353
2023
Q1 		$10.4K Hold
142
– – ﹤0.01% 2188
2022
Q4 		$9.49K Sell
142
-78
-35% -$5.07K ﹤0.01% 2178
2022
Q3 		$12K Buy
220
+60
+38% +$3.53K ﹤0.01% 1987
2022
Q2 		$9K Sell
160
-26
-14% -$1.48K ﹤0.01% 2168
2022
Q1 		$13K Buy
186
+2
+1% +$145 ﹤0.01% 2044
2021
Q4 		$18K Hold
184
– – ﹤0.01% 1833
2021
Q3 		$16K Sell
184
-74
-29% -$5.72K ﹤0.01% 1860
2021
Q2 		$21K Buy
258
+32
+14% +$2.66K ﹤0.01% 1693
2021
Q1 		$21K Sell
226
-10
-4% -$945 ﹤0.01% 1554
2020
Q4 		$15K Sell
236
-86
-27% -$4.9K ﹤0.01% 1554
2020
Q3 		$19K Buy
322
+16
+5% +$1.09K ﹤0.01% 1400
2020
Q2 		$21K Buy
306
+269
+727% +$17.1K ﹤0.01% 1315
2020
Q1 		$2K Buy
+37
New +$2.1K ﹤0.01% 1960
2018
Q4 		– Sell
-1,202
Closed -$206K – 2012
2018
Q3 		$206K Buy
+1,202
New +$181K 0.02% 405

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's LGND Position: Q2 2026 in Review

SignatureFD increased its Ligand Pharmaceuticals (LGND) stake by 0.35% in Q2 2026, buying an estimated $236 and bringing the position to 283 shares worth $89.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

SignatureFD first reported a position in LGND in Q3 2018 and has held it in 27 quarters since. The position peaked at $206K in Q3 2018. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • SignatureFD held 283 shares of Ligand Pharmaceuticals worth $89.5K as of Q2 2026.
  • SignatureFD bought 1 Ligand Pharmaceuticals share in Q2 2026, an estimated $236.
  • Ligand Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1510 holding.
  • SignatureFD first reported a position in Ligand Pharmaceuticals in Q3 2018 and has held it in 27 quarters since.
  • SignatureFD's Ligand Pharmaceuticals position peaked at $206K in Q3 2018.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.